Short Interest in Adaptimmune Therapeutics plc (NASDAQ:ADAP) Decreases By 15.8%

Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) was the recipient of a significant decrease in short interest in April. As of April 15th, there was short interest totalling 4,590,000 shares, a decrease of 15.8% from the March 31st total of 5,450,000 shares. Currently, 2.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,630,000 shares, the short-interest ratio is currently 2.8 days.

Adaptimmune Therapeutics Price Performance

NASDAQ ADAP remained flat at $0.30 on Thursday. 289,453 shares of the company's stock traded hands, compared to its average volume of 1,512,461. The company has a market capitalization of $77.17 million, a price-to-earnings ratio of -1.36 and a beta of 2.86. The stock's fifty day simple moving average is $0.31 and its 200-day simple moving average is $0.53. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. Adaptimmune Therapeutics has a 1 year low of $0.20 and a 1 year high of $1.48.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09). The company had revenue of $3.22 million during the quarter, compared to the consensus estimate of $16.56 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. On average, equities analysts expect that Adaptimmune Therapeutics will post -0.14 EPS for the current year.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Hedge funds have recently bought and sold shares of the company. Two Seas Capital LP acquired a new position in shares of Adaptimmune Therapeutics in the 4th quarter valued at about $7,992,000. Long Focus Capital Management LLC increased its stake in Adaptimmune Therapeutics by 54.1% in the fourth quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company's stock valued at $11,040,000 after purchasing an additional 7,194,503 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Adaptimmune Therapeutics by 52.5% in the fourth quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company's stock worth $1,361,000 after acquiring an additional 869,949 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of Adaptimmune Therapeutics by 87.7% in the fourth quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company's stock valued at $176,000 after buying an additional 152,780 shares in the last quarter. Finally, LPL Financial LLC grew its holdings in shares of Adaptimmune Therapeutics by 106.5% during the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company's stock valued at $99,000 after buying an additional 94,623 shares during the last quarter. Institutional investors own 31.37% of the company's stock.

Wall Street Analyst Weigh In

ADAP has been the topic of a number of recent analyst reports. Scotiabank decreased their price objective on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a research note on Friday, March 21st. StockNews.com initiated coverage on Adaptimmune Therapeutics in a report on Thursday. They set a "buy" rating for the company. Wells Fargo & Company dropped their target price on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a report on Friday, March 21st. Jones Trading lowered shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, April 11th. Finally, Guggenheim dropped their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating for the company in a research note on Wednesday, March 26th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Adaptimmune Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $1.83.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.